Document:

<PAGE>   1
                                                                    Exhibit 10.2

                                VOTING AGREEMENT

         THIS VOTING AGREEMENT is entered into as of October 15, 2000, by and
between Corixa Corporation, a Delaware corporation ("Corixa"), and
_____________________ ("Stockholder").

                                    RECITALS

         A. Corixa, Clearwater Acquisitions Corporation, a Delaware corporation
and a wholly owned subsidiary of Corixa ("Merger Sub"), and Coulter
Pharmaceutical, Inc., a Delaware corporation ("Coulter"), are entering into an
Agreement and Plan of Merger of even date herewith (the "Merger Agreement")
which provides (subject to the conditions set forth therein) for the merger of
Merger Sub into Coulter (the "Merger").

         B. In order to induce CORIXA and Merger Sub to enter into the Merger
Agreement, Stockholder is entering into this Voting Agreement.

                                    AGREEMENT

         The parties to this Voting Agreement, intending to be legally bound,
agree as follows:

SECTION 1. CERTAIN DEFINITIONS

         For purposes of this Voting Agreement:

               (a) All capitalized terms used but not otherwise defined in this
Voting Agreement have the meanings given to them in the Merger Agreement.

               (b) "COULTER COMMON STOCK" shall mean the common stock, $.001 par
value per share, of Coulter.

               (c) "EXPIRATION DATE" shall mean the earlier of (i) the date upon
which the Merger Agreement is validly terminated, or (ii) the date upon which
the Merger becomes effective.

               (d) Stockholder shall be deemed to "OWN" or to have acquired
"OWNERSHIP" of a security if Stockholder: (i) is the record owner of such
security; or (ii) is the "beneficial owner" (within the meaning of Rule 13d-3
under the Securities Exchange Act of 1934) of such security.

               (e) "PERSON" shall mean any (i) individual, (ii) corporation,
limited liability company, partnership or other entity, or (iii) governmental
authority.

                                       1
<PAGE>   2
               (f) "SUBJECT SECURITIES" shall mean: (i) all securities of
Coulter (including all shares of Coulter Common Stock and all options, warrants
and other rights to acquire shares of Coulter Common Stock) Owned by Stockholder
as of the date of this Voting Agreement; and (ii) all additional securities of
Coulter (including all additional shares of Coulter Common Stock and all
additional options, warrants and other rights to acquire shares of Coulter
Common Stock) of which Stockholder acquires Ownership during the period from the
date of this Voting Agreement through the Expiration Date.

               (g) A Person shall be deemed to have a effected a "TRANSFER" of a
security if such Person directly or indirectly: (i) sells, pledges, encumbers,
grants an option with respect to, transfers or disposes of such security or any
interest in such security; or (ii) enters into an agreement or commitment
contemplating the possible sale of, pledge of, encumbrance of, grant of an
option with respect to, transfer of or disposition of such security or any
interest therein.

SECTION 2. RESTRICTIONS ON TRANSFER OF SUBJECT SECURITIES

         2.1 NO TRANSFER OF SUBJECT SECURITIES. Stockholder agrees that, during
the period from the date of this Voting Agreement through the Expiration Date,
Stockholder shall not cause or permit any Transfer of any of the Subject
Securities or any interest therein to be effected, and any such attempted
Transfer shall be null and void; provided, however, that nothing in this Voting
Agreement shall restrict Stockholder's ability to exercise any options to
acquire shares of Coulter Common Stock.

         2.2 NO TRANSFER OF VOTING RIGHTS. Stockholder agrees that, during the
period from the date of this Voting Agreement through the Expiration Date,
Stockholder shall ensure that: (a) none of the Subject Securities is deposited
into a voting trust; and (b) no proxy is granted, and no voting agreement or
similar agreement is entered into, with respect to any of the Subject Securities
(other than pursuant to this Voting Agreement).

SECTION 3. VOTING OF SHARES

         3.1 VOTING AGREEMENT. Stockholder agrees that, during the period from
the date of this Voting Agreement through the Expiration Date:

               (a) at any meeting of stockholders of Coulter, however called,
Stockholder shall cause all outstanding shares of Coulter Common Stock that are
Owned by Stockholder as of the record date fixed for such meeting to be voted:

                  (i) in favor of the adoption of the Merger Agreement and in
         favor of each of the other actions contemplated by the Merger
         Agreement; and

                  (ii) against the following actions (other than the Merger and
         the other transactions contemplated by the Merger Agreement): (A) any
         extraordinary corporate transaction, such as a merger, consolidation or
         other business combination involving

                                       2
<PAGE>   3
         Coulter; (B) any sale, lease or transfer of a material amount of assets
         of Coulter (other than in the ordinary course of business); (C) any
         reorganization, recapitalization, dissolution or liquidation of any of
         Coulter; (D) any removal of or change in a majority of the board of
         directors of Coulter; (E) any amendment to Coulter'S certificate of
         incorporation; (F) any material change in the capitalization of Coulter
         OR Coulter'S corporate structure; and (G) any other action that is
         inconsistent with the Merger or that is intended, or could reasonably
         be expected, to impede, interfere with, delay, postpone, discourage or
         adversely affect the Merger or any of the other transactions
         contemplated by the Merger Agreement or this Voting Agreement;

               (b) in the event written consents are solicited or otherwise
sought from stockholders of Coulter with respect to the adoption of the Merger
Agreement, with respect to the approval of the Merger or with respect to any of
the other actions contemplated by the Merger Agreement, Stockholder shall cause
to be executed, with respect to all outstanding shares of Coulter Common Stock
that are Owned by Stockholder as of the record date fixed for the consent to the
proposed action, a written consent or written consents to such proposed action;
and

               (c) in the event written consents are solicited or otherwise
sought from stockholders of Coulter with respect to any of the matters referred
to in clauses "(A)" through "(G)" of clause "(ii)" of paragraph "(a)" of this
Section 3.1, Stockholder shall cause to be executed, with respect to all
outstanding shares of Coulter Common Stock that are Owned by Stockholder as of
the record date fixed for the consent to the proposed action, a written consent
or written consents against such proposed action.

         3.2 PROXY. Contemporaneously with the execution of this Voting
Agreement: (i) Stockholder shall deliver to Corixa a proxy in the form attached
to this Voting Agreement as Exhibit A, which shall be irrevocable to the fullest
extent permitted by law, with respect to the shares referred to therein (the
"Proxy"); and (ii) Stockholder shall cause to be delivered to Corixa an
additional proxy (in the form attached hereto as Exhibit A) executed on behalf
of the record owner of any outstanding shares of Coulter Common Stock that are
owned beneficially (within the meaning of Rule 13d-3 under the Securities
Exchange Act of 1934), but not of record, by Stockholder.

SECTION 4. WAIVER OF APPRAISAL RIGHTS

         Stockholder hereby irrevocably and unconditionally waives, and agrees
to cause to be waived and to prevent the exercise of, any rights of appraisal,
any dissenters' rights and any similar rights relating to the Merger or any
related transaction that Stockholder or any other Person may have by virtue of
the ownership of any outstanding shares of Coulter Common Stock Owned by
Stockholder.

                                       3
<PAGE>   4
SECTION 5. LOCKUP AGREEMENT

         For a period of ninety (90) calendar days following the Effective Time,
Stockholder shall not Transfer or in any other way reduce Stockholder's risk of
ownership of or investment in any shares of Corixa Common Stock which
Stockholder currently owns or purchases or otherwise acquires after the
execution of this Voting Agreement, whether pursuant to the Merger or otherwise
(including any securities which may be paid as a dividend or otherwise
distributed thereon or with respect thereto or issued or delivered in exchange
or substitution therefor) (all such securities being referred to herein
collectively as "Restricted Corixa Securities"), or any option, right or other
interest with respect to any Restricted Corixa Securities; provided, however,
that nothing in this Agreement shall restrict Stockholder's ability to exercise
options to acquire shares of Corixa Common Stock (it being understood, however,
that any shares of Corixa Common Stock issued to Stockholder upon exercise of
such options shall become "Restricted Corixa Securities" that are subject to the
prohibitions described in this Section 5). Stockholder also understands and
agrees that stop transfer instructions may be given to Corixa's transfer agent
with respect to certificates evidencing the Restricted Corixa Securities to
enforce Stockholder's compliance with this Section 5. Notwithstanding anything
to the contrary contained in this Voting Agreement, this Section 5 shall have no
force or effect if the Merger Agreement is terminated.

SECTION 6. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER

         Stockholder hereby represents and warrants to CORIXA as follows:

          6.1 AUTHORIZATION, ETC. Stockholder has the absolute and unrestricted
right, power, authority and capacity to execute and deliver this Voting
Agreement and the Proxy and to perform his obligations hereunder and thereunder.
This Voting Agreement and the Proxy have been duly executed and delivered by
Stockholder and constitute legal, valid and binding obligations of Stockholder,
enforceable against Stockholder in accordance with their terms, subject to (i)
laws of general application relating to bankruptcy, insolvency and the relief of
debtors, and (ii) rules of law governing specific performance, injunctive relief
and other equitable remedies.

          6.2 NO CONFLICTS OR CONSENTS. The execution and delivery of this
Voting Agreement and the Proxy by Stockholder do not, and the performance of
this Voting Agreement and the Proxy by Stockholder will not: (i) conflict with
or violate any law, rule, regulation, order, decree or judgment applicable to
Stockholder or by which he or any of his properties is or may be bound or
affected; or (ii) result in or constitute (with or without notice or lapse of
time) any breach of or default under, or give to any other Person (with or
without notice or lapse of time) any right of termination, amendment,
acceleration or cancellation of, or result (with or without notice or lapse of
time) in the creation of any encumbrance or restriction on any of the Subject
Securities pursuant to, any contract to which Stockholder is a party or by which
Stockholder or any of his affiliates or properties is or may be bound or
affected. The execution and delivery of this Voting

                                       4
<PAGE>   5
Agreement and the Proxy by Stockholder do not, and the performance of this
Voting Agreement and the Proxy by Stockholder will not, require any consent or
approval of any Person.

          6.3 TITLE TO SECURITIES. As of the date of this Voting Agreement: (a)
Stockholder holds of record (free and clear of any encumbrances or restrictions)
the number of outstanding shares of Coulter Common Stock set forth under the
heading "Shares Held of Record" on the signature page hereof; (b) Stockholder
holds (free and clear of any encumbrances or restrictions) the options, warrants
and other rights to acquire shares of Coulter Common Stock set forth under the
heading "Options and Other Rights" on the signature page hereof; (c) Stockholder
Owns the additional securities of Coulter set forth under the heading
"Additional Securities Beneficially Owned" on the signature page hereof; and (d)
Stockholder does not directly or indirectly Own any shares of capital stock or
other securities of Coulter, or any option, warrant or other right to acquire
(by purchase, conversion or otherwise) any shares of capital stock or other
securities of Coulter, other than the shares and options, warrants and other
rights set forth on the signature page hereof.

          6.4 ACCURACY OF REPRESENTATIONS. The representations and warranties
contained in this Voting Agreement are accurate in all respects as of the date
of this Voting Agreement, will be accurate in all respects at all times through
the Expiration Date and will be accurate in all respects as of the date of the
consummation of the Merger as if made on that date.

SECTION 6 7. MISCELLANEOUS

          7.1 FURTHER ASSURANCES. From time to time and without additional
consideration, Stockholder shall execute and deliver, or cause to be executed
and delivered, such additional transfers, assignments, endorsements, proxies,
consents and other instruments, and shall take such further actions, as CORIXA
may request for the purpose of carrying out and furthering the intent of this
Voting Agreement.

          7.2 NOTICES. Any notice or other communication required or permitted
to be delivered to either party under this Voting Agreement shall be in writing
and shall be deemed properly delivered, given and received (a) when delivered by
hand, or (b) two business days after sent by courier or express delivery service
or by facsimile, to the address or facsimile telephone number set forth beneath
the name of such party below (or to such other address or facsimile telephone
number as such party shall have specified in a written notice given to the other
party):

                  if to Stockholder:

                           at the address set forth below Stockholder's
                           signature on the signature page hereof

                                       5
<PAGE>   6
                  if to Corixa or Merger Sub:

                           Corixa Corp.
                           124 Columbia Street, Suite 200
                           Seattle, Washington 98104
                           Attention:   President
                           Facsimile No.:  (206) 754-5994
                           Telephone No.:  (206) 754-5711

                           Clearwater  Acquisitions Corp.
                           c/o Corixa Corp.
                           124 Columbia Street, Suite 200
                           Seattle, Washington 98104
                           Attention:   President
                           Facsimile No.:  (206) 754-5994
                           Telephone No.:  (206) 754-5711

                  in each case with a copy to:

                           Orrick, Herrington & Sutcliffe LLP
                           701 Fifth Avenue, Suite 6500
                           Seattle, Washington 98104
                           Attention:  Stephen M. Graham
                           Facsimile No.:  (206) 839-4301
                           Telephone No.:  (206) 839-4300

          7.3 SEVERABILITY. If any provision of this Voting Agreement or any
part of any such provision is held under any circumstances to be invalid or
unenforceable in any jurisdiction, then (a) such provision or part thereof
shall, with respect to such circumstances and in such jurisdiction, be deemed
amended to conform to applicable laws so as to be valid and enforceable to the
fullest possible extent, (b) the invalidity or unenforceability of such
provision or part thereof under such circumstances and in such jurisdiction
shall not affect the validity or enforceability of such provision or part
thereof under any other circumstances or in any other jurisdiction, and (c) the
invalidity or unenforceability of such provision or part thereof shall not
affect the validity or enforceability of the remainder of such provision or the
validity or enforceability of any other provision of this Voting Agreement. Each
provision of this Voting Agreement is separable from every other provision of
this Voting Agreement, and each part of each provision of this Voting Agreement
is separable from every other part of such provision.

          7.4 ENTIRE AGREEMENT. This Voting Agreement, the Proxy and any other
documents delivered by the parties in connection herewith constitute the entire
agreement between the parties with respect to the subject matter hereof and
thereof and supersede all prior agreements and understandings between the
parties with respect thereto. No addition to or modification of any provision of
this Voting Agreement shall be binding upon either party unless made in writing
and signed by both parties.

                                       6
<PAGE>   7
          7.5 ASSIGNMENT; BINDING EFFECT. Except as provided herein, neither
this Voting Agreement nor any of the interests or obligations hereunder may be
assigned or delegated by Stockholder and any attempted or purported assignment
or delegation of any of such interests or obligations shall be void. Subject to
the preceding sentence, this Voting Agreement shall be binding upon Stockholder
and his heirs, estate, executors, personal representatives, successors and
assigns, and shall inure to the benefit of Corixa and its successors and
assigns. Without limiting any of the restrictions set forth in Section 2 or
elsewhere in this Voting Agreement, this Voting Agreement shall be binding upon
any Person to whom any Subject Securities are transferred. Nothing in this
Voting Agreement is intended to confer on any Person (other than Corixa and its
successors and assigns) any rights or remedies of any nature.

          7.6 SPECIFIC PERFORMANCE. The parties agree that irreparable damage
would occur in the event that any of the provisions of this Voting Agreement or
the Proxy was not performed in accordance with its specific terms or was
otherwise breached. Stockholder agrees that, in the event of any breach or
threatened breach by Stockholder of any covenant or obligation contained in this
Voting Agreement or in the Proxy, Corixa shall be entitled (in addition to any
other remedy that may be available to it, including monetary damages) to seek
and obtain (a) a decree or order of specific performance to enforce the
observance and performance of such covenant or obligation, and (b) an injunction
restraining such breach or threatened breach. Stockholder further agrees that
neither Corixa nor any other Person shall be required to obtain, furnish or post
any bond or similar instrument in connection with or as a condition to obtaining
any remedy referred to in this Section 7.6, and Stockholder irrevocably waives
any right he may have to require the obtaining, furnishing or posting of any
such bond or similar instrument.

          7.7 GOVERNING LAW; WAIVER OF JURY TRIAL. This Voting Agreement and the
Proxy shall be construed in accordance with, and governed in all respects by,
the laws of the State of Delaware (without giving effect to principles of
conflicts of laws). STOCKHOLDER IRREVOCABLY WAIVES THE RIGHT TO A JURY TRIAL IN
CONNECTION WITH ANY LEGAL PROCEEDING RELATING TO THIS VOTING AGREEMENT OR THE
PROXY OR THE ENFORCEMENT OF ANY PROVISION OF THIS VOTING AGREEMENT OR THE PROXY.

          7.8 COUNTERPARTS. This Voting Agreement may be executed by the parties
in separate counterparts, each of which when so executed and delivered shall be
an original, but all such counterparts shall together constitute one and the
same instrument.

          7.9 CAPTIONS. The captions contained in this Voting Agreement are for
convenience of reference only, shall not be deemed to be a part of this Voting
Agreement and shall not be referred to in connection with the construction or
interpretation of this Voting Agreement.

          7.10 WAIVER. No failure on the part of Corixa to exercise any power,
right, privilege or remedy under this Voting Agreement, and no delay on the part
of Corixa in exercising any power, right, privilege or remedy under this Voting

                                       7
<PAGE>   8
Agreement, shall operate as a waiver of such power, right, privilege or remedy;
and no single or partial exercise of any such power, right, privilege or remedy
shall preclude any other or further exercise thereof or of any other power,
right, privilege or remedy. Corixa shall not be deemed to have waived any claim
available to Corixa arising out of this Voting Agreement, or any power, right,
privilege or remedy of Corixa under this Voting Agreement, unless the waiver of
such claim, power, right, privilege or remedy is expressly set forth in a
written instrument duly executed and delivered on behalf of Corixa; and any such
waiver shall not be applicable or have any effect except in the specific
instance in which it is given.

         7.11 CONSTRUCTION.

               (a) For purposes of this Voting Agreement, whenever the context
requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine
gender shall include the masculine and neuter genders; and the neuter gender
shall include masculine and feminine genders.

               (b) The parties agree that any rule of construction to the effect
that ambiguities are to be resolved against the drafting party shall not be
applied in the construction or interpretation of this Voting Agreement.

               (c) As used in this Voting Agreement, the words "include" and
"including," and variations thereof, shall not be deemed to be terms of
limitation, but rather shall be deemed to be followed by the words "without
limitation."

               (d) Except as otherwise indicated, all references in this Voting
Agreement to "Sections" and "Exhibits" are intended to refer to Sections of this
Voting Agreement and Exhibits to this Voting Agreement.

                                       8
<PAGE>   9
         IN WITNESS WHEREOF, Corixa and Stockholder have caused this Voting
Agreement to be executed as of the date first written above.

                                   CORIXA CORPORATION

                                   By:
                                        ---------------------------------------

                                   Name:
                                          -------------------------------------
                                   Title:
                                          -------------------------------------

                                   STOCKHOLDER

                                   -----------------------------------
                                             (Signature)

                                   -----------------------------------
                                              (Print Name)

                                   Address:
                                               -------------------------------

                                               -------------------------------

                                               -------------------------------

                                   Facsimile:
                                               -------------------------------

<TABLE>
<CAPTION>

          Shares Held of Record             Options and Other Rights               Additional Securities
          ---------------------             ------------------------               ---------------------
                                                                                   Beneficially Owned
                                                                                   ------------------
<S>                                         <C>                                    <C>
Common Stock                                Common Stock
             --------------                              --------------

</TABLE>

                                       9EXHIBIT 10.24

                                    AGREEMENT

     This Agreement (the  "Agreement")  dated as of November __, 1999 is made by
and between Carter BloodCare ("CBC") a Texas not-for-profit  corporation,  whose
principal  offices are located at 2201  Highway 12 1,  Bedford,  Texas,  7602 1,
Bloodcare Foundation  ("Foundation") a Texas not-for-profit  corporation,  whose
principal  offices are located at 2201 Highway 121,  Bedford,  Texas,  76021 and
Hemocare ("Hemocare"),  the blood bank division of Mediware Information Systems,
Inc. a New York  corporation,  whose  principal  offices are located at 1121 Old
Walt Whitman Road, Melville, New York 11747.

                                    RECITALS

(A) CBC has developed a computer software package ("LifeTrak(TM)/Donor module"
or "Donor Software") for use in managing information required for recruitment,
collection, and donor registration and deferral activities of donor blood
centers, and on September 15, 1999 submitted an Abbreviated 510(k) to the Food
and Drug Administration ("FDA") to secure FDA clearance for the LifeTrak(TM)
/Donor module;

(B) CBC has developed a computer software package "LifeTrak(TM)/Distribution
module" or "Distribution Software") for use by donor blood centers in managing
the information required for blood products inventory and distribution
activities, and on October 14, 1999 CBC received the FDA clearance for the
LifeTrak(TM)/Distribution module;

(C) CBC has developed a computer software package "LifeTrak(TM)/Lab Module" or "
Lab Software") for use by donor blood centers in managing information about
material check-in, special processing, component preparation, testing, and
labeling; and on October 1, 1998 CBC received the FDA clearance for the
LifeTrak(TM)/Lab Module. CBC has granted to a single third party licensee
("Third Party Licensee") a license (the "Third Party License") to a set of
testing functionality's from LifeTrak(TM)/Lab as a separate module,
("LifeTrak(TM)/Lab- Central Testing Facility" or " CTF Software"). A portion of
the CTF Software (the "Exclusive Module") is exclusively licensed to the Third
Party Licensee through December 31, 2002, and non-exclusively licensed
thereafter;

(D) The Donor Software, the Distribution Software and the Lab Software are
referred to collectively as the "Donor/Distribution/Lab Software" or as the
"Software", and each module has been described in a document previously
delivered by CBC to Hemocare and initialed by both parties; and

(E) CBC will transfer title to the Exclusive Module of the CTF Software to
Hemocare on or about January 1, 2003, subject to the continuing non-exclusive
license to all of the CTF Software (including the Exclusive Module), to the
Third Party License; and

(F) Hemocare has been engaged in providing computer software for use by
transfusion blood banks and hospitals in managing their information requirements
for approximately two decades and wishes to acquire the Donor/Distribution/ Lab
Software identified above and to develop and market the same for the mutual
benefit of the parties hereto. CBC wishes to obtain a non-exclusive,
royalty-free, nonassignable, and perpetual license for CBC to use the Software
internally and not for use by third parties or for sale, transfer, license or
sublicense by CBC.

                                       1
<PAGE>

NOW THEREFORE, in consideration of the mutual promises and covenants herein
contained and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, CBC and Hemocare do each hereby
agree as follows:

Section 1. Purchase and Sale of Software.

The purchase price to be paid by Hemocare to CBC for the Software will be
$1,500,000, payable in cash; the first payment of $750,000 being payable upon
delivery to Hemocare of the "Initial Deliverables" (as provided in Section 2(b)
below), a payment of $375,000 being due when FDA Clearance is received for the
Donor Software and a payment of $375,000 being due on June 30, 2000. Upon
payment of the first $750,000, the following shall occur:

(a) CBC will convey to Hemocare ownership of the Software, with the exception of
the Exclusive Module, and deliver to Hemocare the Initial Deliverables as
provided in Section 2 below, and

(b) CBC will transfer and assign the 510(k) applications or clearance for the
Software to Hemocare; and

(c) Hemocare will become the owner of the product and software name:
"LifeTrak(TM)", and

(d) Hemocare and CBC will execute a license agreement in the form previously
agreed upon between the parties ("License Agreement") under which Hemocare will
license to CBC the right to continue use of the Software in CBCs blood center
and laboratory facilities.

Section 2. Prosecution of Application for Clearance by FDA; Transfer; CTF
Software.

(a) Hemocare will use best efforts to secure clearance from the FDA for the
LifeTrak(TM)/Donor Module and will respond expeditiously to requests of the FDA
relating to clearance of the LifeTrak(TM)/Donor Module and CBC will cooperate
fully with Hemocare in seeking such clearance. In the event Hemocare wishes to
have CBC personnel travel to or meet with FDA personnel or third parties in
connection with obtaining such approvals, Hemocare agrees to pay the
out-of-pocket expenses of the CBC personnel so involved. Personnel costs
associated with obtaining clearance from the FDA shall be borne as follows: (i)
the first $25,000 by Hemocare; (ii) the cost above $25,000 up to $50,000 by CBC;
and (iii) costs in excess of $50,000 shall be shared equally. For the purposes
of this Section, the cost of any person shall be considered at $50 per hour.
Hemocare will keep CBC informed of any communication, written or oral, received
from the FDA with respect to the 510(k)s and Hemocare will consult with CBC in
developing a plan for the appropriate response.

(b) On or before October 29, 1999, CBC shall deliver to Hemocare a copy of the
source and machine codes and the technical documentation for the Software, other
than the Exclusive Module, on CDROM (the "Initial Deliverables"), and no later
than sixty (60) days after signing of this Agreement CBC shall deliver (i) to
Hemocare, at its Dallas, Texas offices the remaining hard copy documentation and
all other deliverables necessary to use, enhance, market and support the
Software, and (ii) to an escrow agent to be selected a copy of the source codes,
documentation and all other appropriate deliverables, including an executed bill
of sale with an effective date of January 1, 2003, for the CBC version of the
CTF Software which was submitted to the FDA in CBC's Abbreviated 510(k)s and is
in use by CBC. The escrow agent will be instructed to deliver the documents of
transfer and the escrowed source code and other deliverables to Hemocare on
January 2, 2003. The transfer of ownership shall take place automatically
without the need for further action by CBC, but the agent will notify CBC at the
time of the transfer. Simultaneously with the effectiveness of the Bill of Sale
for the CTF Software, the License Agreement shall automatically be amended to
include the CTF Software. In the event CBC obtains enhancements to the CTF
Software during the escrow period that are assignable or sub-licensable to
Hemocare, CBC agrees to assign or sublicense such rights to Hemocare. CBC makes
no representation that there will be any enhancements to the CTF Software made
after the date hereof that are deliverable to Hemocare.

                                       2
<PAGE>

Section 3. Additional Purchase Price Payments.

(a) Additional purchase price payments will be made by Hemocare within 30 days
after the end of each calendar quarter in the amount of 5% of "Sales" of the
Software. "Sales" shall be calculated as the gross proceeds received by Hemocare
for the license or sale of Software or any module thereof less deductions from
such proceeds for any returns. The pricing of the Software shall be determined
by Hemocare. No additional purchase price payments will be paid on hardware,
implementation, installation, support and similar services or on computer
software developed by Hemocare or any third party (other than the Third Party
Licensee). In the event Hemocare sells the Software with other goods or services
the Software will be priced separately, Payments of additional purchase price
will be made on all Software sold during a period of five years commencing on
the date FDA Clearance is received for the Donor Software.

(b) Payments of additional purchase price installments will be made by Hemocare
to CBC at the rate of 5% of Sales of the Exclusive Module on the same basis as
the other LifeTrak(TM)Software. Such additional purchase price obligation will
be in effect and payment will be owing for a five-year period beginning when
title to the Exclusive Module is effectively transferred to Hemocare by CBC at
the expiration of the escrow period for the Exclusive Module. Such additional
purchase price payments will continue for all sales of the Exclusive Module made
within the five-year period.

(c) There will be no required minimum annual payments to be made by Hemocare to
CBC under this Section.

(d) CBC may, upon reasonable prior written notice to Hemocare, have an
independent auditor audit the books and records of Hemocare to ensure proper
payment of all additional payments hereunder. Such audit shall not be performed
more than once per year. In the event the audit reveals an underpayment Hemocare
shall promptly remit the amount of the underpayment plus interest thereon at the
lesser of (i) the prime lending rate quoted by CitiBank N.A. from time to time,
or (ii) the maximum rate allowed by law. In the event such audit reveals an
underpayment in excess of 11%, Hemocare will reimburse to CBC the third party
costs of the audit.

(e) In the event that Hemocare utilizes the Software in a service bureau or
similar operation, Hemocare shall pay to CBC a payment on the revenues generated
thereby equivalent to the additional purchase price payments that would have
been generated by a direct license or sale of the Software, and the parties
agree to negotiate in good faith a method for calculating and accounting for
such revenues.

Section 4. Develoment of New Testing Software Module.

Hemocare will develop a testing software module at its expense and will use its
best efforts to obtain FDA approval of such testing software module. Such module
would be developed separately from the development and enhancement of the CTF
Software developed by CBC, and will be licensed to CBC pursuant to the License
Agreement.

Section 5. Improvements, Modifications and Enhancements.

(a) All improvements, modifications and enhancements made by Hemocare to the
Software will be made available to CBC under the License Agreement without any
additional payments, purchase price installments, royalties or similar payments
by CBC. Hemocare will provide same to CBC at such time as and in the form that
they are made available to other licensees of Hemocare.

(b) Commencing upon delivery of the Software, and during the 7-year period
thereafter, CBC may request that Hemocare develop custom enhancements to the
Software for use by CBC, and Hemocare may request consulting assistance from CBC
with respect to the Software. CBC may elect whether or not to allow Hemocare to
incorporate any such custom enhancements in any future release of the

                                       3
<PAGE>

Software or Enhancements. In the event CBC elects not to allow Hemocare to
incorporate such custom enhancements, Hemocare will provide CBC with the source
code for the custom enhancements and CBC acknowledges that Hemocare will not be
obligated to support such custom enhancements. Hemocare will make available to
CBC Enhancements resulting from custom enhancements made by Hemocare for other
Hemocare licensees of general use and applicability to its licensees. Such
consulting services shall be rendered to the other party on the terms set forth
in the Consulting Services Agreement attached hereto as Exhibit A.

(c) In addition to the consulting provided in (b) above, Hemocare will make
available to CBC consulting services as requested by CBC to facilitate support
obligations owed by CBC to the Third Party Licensee or any sub-licensee of the
Third Party Licensee. Such support shall be defined and at a monthly or similar
rate as mutually agreed by the parties, but in no event less than Hemocare's
fully loaded costs for such personnel nor more than charged by Hemocare for
similar support to its other customers. Consulting Services under this Section
(c) shall be subject to CBC providing Hemocare adequate access to the computer
code necessary to enable such consulting to be performed in a professional
manner. If required by the Third party Licensee such computer code will be
maintained as confidential by Hemocare.

Section 6. Hardware.

With the concurrence of CBC, Hemocare will conduct an evaluation of the present
hardware owned or used by CBC at its facility in Dallas for possible acquisition
by Hemocare at depreciated book value, as mutually agreed upon by both parties.

Section 7. Restrictions on Distribution and Licensing or Sublicensing of CTF
Software, and related Documentation and Improvements.

Hemocare agrees that, except as otherwise agreed in writing, it shall not
distribute, license or sublicense the CTF Software and related documentation or
enhancements to any third party unless such third party first acknowledges in
writing that the CTF Software and related documentation and enhancements are
trade secrets of Hemocare, and a not to disclose or to use the CTF Software and
related documentation and enhancements for any purpose other than that for which
the applicable license or sublicense is granted. Except as necessary for
development, maintenance, or Source Code escrow, Hemocare shall only distribute
the Object Code version of the CTF Software and enhancements thereto.

Section 8. Confidentially

Hemocare will not disclose and shall use commercially reasonable efforts to
ensure that no existing or future employees of Hemocare shall disclose any
information designated as confidential or trade secret information of CBC, the
Third Party Licensee or any third party clients, donors, or licenses of CBC. CBC
will not disclose and shall use commercially reasonable efforts to ensure that
no existing or future employees of CBC shall disclose any information designated
as confidential or trade secret information of Hemocare or any third party
clients, donors, or licenses of Hemocare.

Section 9. Intellectual Property Rights

Upon the signing of this Agreement, the intellectual property rights relating to
each of the LifeTrak modules, Donor, Distribution, and Lab (with the exception
of the Exclusive Module), together with any modifications, developments,
improvements, changes or enhancements relating to such products made by either
Hemocare or CBC, shall be, as between the parties hereto, the sole and exclusive
property of Hemocare provided, that the intellectual property rights of Hemocare
relating to the CTF Software will

                                       4
<PAGE>

be subject to the rights of the Third Party Licensee, as contained in the Third
Party License. Notwithstanding the foregoing, CBC shall not assign to Hemocare
any confidential or trade secret information of any third party.

Section 10. Understanding.

This Agreement, together with all exhibits and attachments, constitutes the
entire understanding between the parties with respect to the subject matter
contained herein, other than the license agreement and supersedes and cancels
all prior understandings, agreements and arrangements between the parties,
written or oral with respect thereto.

Section 11. Representations.

(a) Each party represents that it has the full right and authority to enter into
this Agreement and is not aware of any impediments which would inhibit its
ability to perform its obligations under this Agreement. CBC warrants that it
owns the source code for the Software that has been submitted to the FDA, with
the exception of the license rights of the Third Party Licensee in the Software
for the term of the Third Party License, and that to the best of its knowledge
the source codes and remainder of the Software do not infringe on any existing
patents, proprietary rights or contractual rights of third parties. CBC
represents that the Donor Software, the Distribution Software and the Lab
Software (with the exception of the Exclusive Module) to be delivered to
Hemocare hereunder constitute the same software as presently used by CBC in its
donor blood centers, and will conform in all material respects to the 510(k)
applications presently on file with their FDA. Hemocare represents to CBC that
improvements, modifications and enhancements included in the future in the
Software by Hemocare will not, to the best of the knowledge of Hemocare at the
time of inclusion, infringe on any existing patents, proprietary rights or
contractual rights of third parties.

(b) OTHER THAN TEE REPRESENTATIONS OF CBC TO HEMOCARE AND THE REPRESENTATIONS OF
HEMOCARE TO CBC IN SECTION II (a) OF THIS PURCHASE AGREEMENT (a) NEITHER
HEMOCARE OR CBC MAKES ANY REPRESENTATIONS OR WARRANTIES TO EACH OTHER OR TO ANY
PARTY OF ANY KIND, WHETHER EXPRESS OR IMPLIED WITH RESPECT TO THE LICENSE
AGREEMENT, THIS PURCHASE AGREEMENT, OR OTHERWISE WITH RESPECT TO THE SOFTWARE,
OR ANY FDA FILING, OR WITH RESPECT TO ANY SERVICES OR GOODS PROVIDED BY CBC TO
HEMOCARE OR BY HEMOCARE TO CBC UNDER THE LICENSE AGREEMENT, THIS PURCHASE
AGREEMENT, OR OTHERWISE IN CONNECTION WITH THE SOFTWARE, INCLUDING, BUT NOT
LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE, AND (b) NEITHER HEMOCARE OR CBC MAKES ANY REPRESENTATIONS OR
WARRANTIES TO EACH OTHER OR TO ANY PARTY OF ANY KIND, WHETHER EXPRESS OR IMPLIED
WITH RESPECT TO THE LICENSE AGREEMENT, THIS PURCHASE AGREEMENT, OR OTHERWISE
WITH RESPECT TO THE LIKELIHOOD THAT ANY FDA FILING WILL BE ACCEPTED OR
CLEARANCES GRANTED BY THE FDA, AND NO ASSURANCES ARE BEING GIVEN BY CBC HEREIN
THAT THE FDA WILL ACCEPT OR GRANT CLEARANCE TO SUCH FILING OR THAT ADDITIONAL
FILINGS WILL NOT BE REQUIRED BY THE FDA.

(c) The obligation of either party with respect to confidential information of
another party shall be to treat same in the same manner as the receiving party
treats its own confidential information.

Section 12. Exclusion of Consequential Damages.

IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY CONSEQUENTIAL,
INDIRECT, SPECIAL OR INCIDENTAL DAMAGES, INCLUDING LOST PROFITS, LOSS OF
BUSINESS OR OTHER ECONOMIC DAMAGES, AND FURTHER

                                       5
<PAGE>

INCLUDING INJURY TO PROPERTY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH POTENTIAL LOSS OR DAMAGE.

Section 13. Amendments and Waivers.

Neither this Agreement nor any terms hereof or exhibits hereto may be amended,
supplemented, modified or waived except by an instrument in writing signed by
both parties.

Section 14. BloodCare Foundation.

CBC has assigned certain rights with respect to the Software to the Foundation.
By execution hereof, the Foundation consents to the terms of this Agreement and
agrees that the consummation of the transactions herein will not constitute a
breach of any agreements to which the Foundation is a party; provided, however,
that nothing herein shall be deemed an amendment of any agreements between CBC
and the Foundation.

Section 15. Notices.

All notices required or permitted under this Agreement will be deemed given: (a)
when delivered personally; (b) when sent by confirmed facsimile; (c) seven (7)
days after having been sent by registered or certified mail, return receipt
requested, postage prepaid; or (d) the next business day after deposit with a
commercial overnight carrier specifying next-day delivery, with written
verification of receipt. All communications will be sent to the addresses set
forth below (or to such other address as may be designated by a party by giving
written notice to the other party pursuant to this Section).

Hemocare:

Hemocare Inc.
1121 Old Wait Whitman Road
Melville, New York 11747-3005
Tel: (516) 423-7800

Carter BloodCare:

Carter Blood Care
2205 Highway 121
Bedford, Texas 76021

BloodCare Foundation:

BloodCare Foundation
2205 Highway 121
Bedford, Texas 76021

Section 16. Arbitration.

Any controversy or claim between the parties arising out of, or relating to,
this Agreement or its performance or breach shall be settled by arbitration in
accordance with the Commercial Arbitration rules of the American Arbitration
Association and judgment entered upon the award by the arbitrator may be entered
in any court having jurisdiction thereof. In the event CBC is the party
requesting arbitration the proceedings will be conducted in New York, New York.
In the event Hemocare is the party requesting arbitration the proceedings will
be conducted in Dallas, Texas.

                                       6
<PAGE>

Section 17. Governing Law.

This Agreement shall be governed by, and construed in accordance with, the law
of State of Texas without regard for conflicts of law rules.

Section 18. Counterparts.

This Agreement may be executed in counterparts, each of which shall be deemed an
original and all of which together shall constitute one and the same instrument.

 CARTER BLOODCARE                            BLOODCARE FOUNDATION

By:    /s/  MH Sayers                        By:    /s/  MH Sayers
       ------------------------                     ------------------------

Name:  M.H. Sayers                           Name:  M.H. Sayers
       ------------------------                     ------------------------

Title: CEO                                   Title  Member Representative
       ------------------------                     ------------------------

Hemocare, A DIVISION OF MEDIWARE INFORMATION SYSTEMS, INC.

By:    /s/ Lawrence Auriana
       ------------------------

Name:  Lawrence Auriana
       ------------------------

Title: Chairman-Secretary
       ------------------------

                                       7
<PAGE>

EXHIBIT A

                           MUTUAL CONSULTING SERVICES

This Consulting Services Agreement ( "Consulting Agreement") dated as of
November ___, 1999 is made by and between Carter BloodCare ("CBC") a Texas
not-for-profit corporation, whose principal offices are located at 2201 Highway
121, Bedford, Texas, 76021, Bloodcare Foundation ("Foundation") a Texas
not-for-profit corporation, whose principal offices are located at 2201 Highway
121, Bedford, Texas, 76021 and Hemocare ("Hemocare"), the blood bank division of
Mediware Information Systems, Inc. a New York corporation, whose principal
offices are located at 1121 Old Walt Whitman Road, Melville, New York 11747.

WHEREAS pursuant to an agreement of even date herewith (the "Sale Agreement")
CBC has agreed to sell and Hemocare has agreed to purchase certain software and
related materials; and

WHEREAS CBC and Hemocare desire to provide certain consulting services to one
another on terms and subject to the conditions set forth herein,

NOW THEREFORE, CBC and Hemocare agree as follows:

1, Terms defined in the Sale Agreement shall have the same meaning when used
herein.

2. Upon reasonable prior request, each party agrees to provide consulting
services to the other in the field of information management for donor blood
banks (the "Field"), and shall be separate from any obligations to develop
enhancements, modifications or support under the Sale Agreement or the License
Agreement.

3. Consulting by CBC shall be subject to the availability of CBC personnel to
provide consulting, and nothing herein shall obligate CBC to hire or retain the
services of any particular person or number of consulting personnel. Consulting
by Hemocare shall be subject to the availability of Hemocare personnel in the
ordinary course of Hemocare's business.

4. Each party shall designate consulting personnel as either junior or senior
based on years of experience and training. Fees for junior personnel shall be
$50 per hour and for senior personnel shall be $75 per hour, The fee schedule
will be reviewed annually by the parties and may be increased upon mutual
consent consistent with prevailing industry rates. In the event such rates are
not adequate to compensate a party for its costs associated with such personnel,
the parties agree to raise the rates as necessary to reach at least a break even
position until the next annual review.

5. Consulting by either party shall be performed in a good and workmanlike
manner consistent with best industry practices.

6. Each party shall responsible for wages, benefits, workers compensation,
unemployment and similar charges associated with the consultants it makes
available to the other party.

7. Nothing contained herein shall obligate a party to utilize any minimum amount
of consulting services from the other.

8. In the event consulting services are provided at the offices of the other
party, the other party shall provide a safe work environment for such personnel.

9. This Agreement shall be governed by, and construed in accordance with, the
law of State of Texas without regard for conflicts of law rules.

10. This Agreement may be executed in counterparts, each of which shall be
deemed an original and all of which together shall constitute one and the same
instrument.

CARTER BLOODCARE

By:   /s/ MH Sayers
      --------------------------

Hemocare, A DIVISION OF
MEDIWARE INFORMATION SYSTEMS, INC.

By:   /s/ Lawrence Auriana
      --------------------------
Its Chairman

                                       8
<PAGE>

Hemocare Division
Mediware Information Systems, Inc.
1121 Old Wait Whitman Road, Melville, New York 11747,

Gentlemen:

This letter is with respect to that certain Purchase Agreement ("Purchase
Agreement") of even date hereof governing the purchase and sale of certain
software for the information management for donor blood banks.

Notwithstanding anything contained to the contrary in the Purchase Agreement or
the license agreement or exhibits referenced therein, the parties agree to a
transition period for the transfer of the Software and for certain personnel and
officing matters as follows:

1. The period beginning upon execution hereof and ending sixty (60) days
thereafter shall be defined as the "Transition Period". CBC has previously
identified to Hemocare those employees of CBC primarily engaged in the support
of the Software (the "Software Employees"). As soon as practicable CBC and
Hemocare will review the various skills and past work assignments of the
Software Employees. Within five days of completion of that review Hemocare will
identify to CBC the Software Employees that Hemocare desires to hire. Hemocare
may thereafter meet with and make offers of employment to that subset of the
Software Employees; provided that such offers will be no less than the present
salaries of such employees, and will provide for such Software Employees to
become employees of Hemocare no later than the end of the Transition Period.
Hemocare agrees to give all Software Employees hired by Hemocare pursuant to the
Agreement credit for such employee's past service at CBC for the purposes of
determining seniority, vacation and severance benefits and eligibility under any
other Hemocare employee benefit plans.

2. During the Transition Period CBC may have the Software Employees assist CBC
directly in supporting the Software for CBC. Hemocare's obligation to support
the Software, and CBC's obligation to pay Hemocare for such support shall begin
on the earlier of (a) the transition to Hemocare's payroll of at least one-half
of the Software Employees or the end of the Transition Period. During the
Transition Period CBC will cooperate with Hemocare in providing access to the
Software Employees for the purposes of interviewing and conducting the hiring
process. CBC makes no representation as to the willingness of any particular
Software Employee to enter the employment of Hemocare.

3. During the Transition Period, CBC agrees to negotiate in good faith with
Hemocare the subletting of a portion of the space occupied by CBC in its Dallas,
Texas facility for the use of the Software Employees. Such subletting shall be
at the cost per square foot allocated by CBC during the term hereof to its
internal business units, which presently is $15 per square foot. Any such
negotiations shall be subject to the then existing and anticipated needs of CBC
for office space for the conduct of its own operations; provided, however, that
CBC shall make available for subletting an amount of space equal to that
presently occupied by those Software Employees who become Hemocare employees.

                                       9
<PAGE>

Please indicate your assent to the foregoing in the space provided below.

Very truly yours,

CARTER BLOODCARE

By:  /s/ MH Sayers
     ----------------------

Accepted this __day of November, 1999

Hemocare, A DIVISION OF
MEDIWARE INFORMATION SYSTEMS, INC.

By:  /s/ Lawrence Auriana
     ----------------------
Its Chairman

                                       10
<PAGE>

                           SOFTWARE LICENSE AGREEMINT

     Software  License  Agreement  dated  November 1, 1999 by and between Carter
BloodCare,   a  Texas   not-for-profit   corporation   ("CBC"),   and   Hemocare
("Hemocare"),  the blood bank division of Mediware Information Systems,  Inc., a
New York corporation.

     WHEREAS  pursuant to an agreement  of even date between the parties  hereto
(the  "Purchase  Agreement"),  Hemocare  has  acquired  ownership  of a computer
software  package  for use in managing  the  information  requirements  of donor
identification  and the related  aspects of donor  blood banks  ("LifeTrak/Donor
Module" or "Donor  Software"),  a computer  software package for use in managing
the information requirements of the distribution operations of donor blood banks
and hospitals ("LifeTrak/Distribution Module" or "Distribution Software"), and a
computer  software  package for use in managing the information  requirements of
the testing and laboratory system of a donor blood bank ( "LifeTrak/Lab  Module"
or "Lab Software"). Provided that a module ("Exclusive Module") contained in the
Central Testing  Facility  software ("CTF  Software") of the Lab Software is the
subject of an exclusive  license ("Third Party  Agreement")  from CBC to a third
party  ("Third  Party") as described in the Purchase  Agreement  and will not be
subject to this License  Agreement until January 1, 2003, upon expiration of the
exclusivity provisions of the Third Party Agreement.  On that date Hemocare will
acquire a title to the Exclusive Module, subject to the continuing non-exclusive
license rights of the Third Party to the CTF Software.  A fuller  description of
the Donor Software, Distribution Software and Lab Software (together "Software")
is contained in Exhibit A to the  Purchase  Agreement.  For the purposes of this
License Agreement the term "CBC" includes its branch offices operating under its
Food and Drug Administration ("FDA") license.

     In  consideration  of the mutual  premises and agreements set forth in this
License Agreement, and other good and sufficient consideration,  the receipt and
sufficiency of which is hereby acknowledged, Hemocare and CBC agree as follows:

     1. License.  Subject to, and in accordance  with, the terms of this License
Agreement,  Hemocare grants to CBC and CBC accepts from Hemocare a nonexclusive,

                                       11
<PAGE>

perpetual,  royalty  free  license  (which is not  transferable  by  conveyance,
assignment,  license,  sub-license or otherwise)  (the "License") to install and
use the  Software  for the  purposes  for which it was  designed on the computer
equipment of CBC,  solely for the internal  business of CBC. This license covers
all  developments,  modifications,  improvements  and  enhancements to the Donor
Software.  Distribution  Software. the Lab Software, the lab module be developed
by  Hemocare  (and after  January 1, 2000 the  Exclusive  Module);  and  related
documentation  and  deliverables.  CBC shall have the right to create derivative
works in addition to improvements,  modifications  and enhancements  provided by
Hemocare,  of the Software  (a) for use by CBC but not for use by any  licensee,
sub-licensee  or  transferee  of CBC and (b) for  inclusion  by  Hemocare in the
Software   releases   made   available   generally   to   Hemocare's   customers
 ...Sub-derivative  works developed by CBC will be the property of CBC subject to
the pre-existing  ownership of Hemocare of the Software,  the other  proprietary
rights of Hemocare in the  Software,  and the right of Hemocare to use,  modify,
license and sublicense the derivative  work in Software  releases made available
generally to Hemocare's  customers as aforesaid.  Hemocare shall not be required
to support derivative works created by CBC and used by CBC.

     2. Effective Date. This License shall become effective on the date that the
LifeTrak/Donor,  LifeTrak Distribution and LifeTrak/Lab products are transferred
from CBC to Hemocare and shall remain in full force and effect in perpetuity.

     3. Delivery of Software.  The Software has been  delivered and installed on
the  computer  hardware of CBC's donor blood banks and is in  operation  at such
donor blood banks.

     4.  Delivery  of  Enhancements.  Hemocare  shall  deliver  to CBC any code,
instructions  and  documentation to be used in supporting the Software in effect
and  available  at the time that this  License  Agreement  goes into  effect not
already in the possession of CBC. Tbereafter improvements,

                                       12
<PAGE>

modifications   and  enhancements  of  the  Software   (including  source  code,
instructions  and other  documentation)  will be delivered by Hemocare to CBC as
provided in Section 5.

     5.  Modifications  and Enhancements.  All  improvements,  modifications and
enhancements made by Hemocare to the Donor Software,  Distribution Software, the
Lab Software (and the Exclusive Module when it becomes available under the Third
Party  Agreement)  will be made  available to CBC under this  License  Agreement
without additional payments,  purchase price installments,  royalties or similar
payments  by  CBC.  Upon  the  request  of  CBC,   Hemocare  will  provide  such
improvements,  modifications  and enhancements to CBC when made available to the
other customers of Hemocare.

     6.  Requested  Enhancements.   Upon  request  by  CBC,  Hemocare  will  use
reasonable  efforts  to  develop  enhancements  specified  by CBC for  its  use.
Hemocare may modify, use, license and sublicense the enhancements  developed for
CBC and for the use of its other customers without additional payments, purchase
price installments,  royalties or similar payments by Hemocare to CBC. CBC shall
pay Hemocare for the development of enhancements  made at the request of CBC the
hourly rate(s) and expenses stated in Schedule A.

     7. Software Support. During the 7-year period following the signing of this
License  Agreement  Hemocare will provide  ongoing  software  support to the CBC
blood banks,  including all improvements,  modifications and enhancements to the
Software made available to its customers  generally,  which support will be made
available  to CBC at a price of $.875  per unit.  This  customer  support  shall
include the services and response  agreed  between the parties  based on support
services  provided  generally  by  Hemocare to  licensees  of its  software.  In
furtherance  of the  forgoing,  the parties will  promptly  develop,  and put in
writing,  mutually acceptable service and response  standards.  Payment for such
support shall be on a calendar  quarterly  basis and be due within 45 days after
the end of each quarter. Hemocare will make available to CBC consulting services
as requested by CBC to facilitate  support  obligations owed by CBC to the Third
Party at the rates set forth in Schedule A.

                                       13
<PAGE>

     8.  Warranty.  OTHER THAN THE  REPRESENTATIONS  OF CBC TO HEMOCARE  AND THE
REPRESENTATIONS OF HEMOCARE TO CBC IN SECTION 11(a) OF THIS PURCHASE  AGREEMENT,
(a) NEITHER  HEMOCARE OR CBC MAKES ANY  REPRESENTATIONS  OR  WARRANTIES  TO EACH
OTHER OR TO ANY PARTY OF ANY KIND,  WHETHER EXPRESS OR IMPLIED,  WITH RESPECT TO
THIS LICENSE AGREEMENT, THE PURCHASE AGREEMENT, OR OTHERWISE WITH RESPECT TO THE
SOFTWARE,  OR ANY FDA FILINGS, OR WITH RESPECT TO ANY SERVICES OR GOODS PROVIDED
BY CBC TO  HEMOCARE  OR BY HEMOCARE  TO CBC UNDER THIS  LICENSE  AGREEMENT,  THE
PURCHASE AGREEMENT OR OTHERWISE IN CONNECTI0N WITH THE SOFTWARE,  INCLUDING, BUT
NOT LIMITED  TO, ANY  IMPLIED  WARRANTIES  OF  MERCHANTABILITY  OR FITNESS FOR A
PARTICULAR PURPOSE,  AND (b) NEITHER HEMOCARE OR CBC MAKES ANY REPRESENTATION OR
WARRANTY TO EACH OTHER OR TO ANY OTHER PARTY UNDER THIS LICENSE  AGREEMENT,  THE
PURCHASE  AGREEMENT OR OTHERWISE  WITH  RESPECT TO THE  LIKELIHOOD  THAT ANY FDA
FILINGSS  WILL BE ACCEPTED OR  CLEARANCES  GRANTED BY THE FDA, AND NO ASSURANCES
ARE BEING  GIVEN BY HEMOCARE OR CBC THAT THE FDA WILL ACCEPT OR APPROVE OR GRANT
CLEARANCE TO SUCH FILINGSS OR THAT  ADDITIONAL  FILINGSS WILL NOT BE REQUIRED BY
THE FDA.

     9.  Non-disclosure.  Each of CBC and Hemocare will use its best efforts and
at  least  the  same  degree  of care it uses to  protect  its own  confidential
information of like importance to prevent  unauthorized  use,  dissemination and
disclosure  of all  confidential  and  proprietary  information  concerning  the
Software.  Each party agrees that it shall (a) leave in place any proprietary or
confidential  legends or marking placed on any product,  (b) restrict disclosure
of  confidential  information to those of its employees,  consultants and agents
who need to know such  information  and (c) instruct and require such employees,
consultants and agents to maintain the confidentiality of such information.  The
obligations relating to confidential information shall continue through the term
of

                                       14
<PAGE>

this License  Agreement and thereafter for so long as such information is deemed
confidential by the disclosing party.

     10. Propriety Right. CBC agrees and recognizes that (except as specifically
set forth in Section I of this License  Agreement):  (a) the Software,  together
with any other data and  materials  supplied by Hemocare to CBC  pursuant to the
Agreement,  is the property of Hemocare and remain so after  licensing to CBC or
held by CBC on the date of this  License  Agreement;  (b) the  software  and any
other  instructions,  data and  deliverables  supplied  by  Hemocare  to CBC, in
machine  readable form or otherwise,  are  confidential  and  proprietary  trade
secrets of Hemocare, protected by law, and of substantial value to Hemocare, and
their use and disclosure must be carefully and continuously controlled;  and (c)
the  Software is  protected  by the  copyright  laws of the United  States.  The
Software  licensed  under this  License  Agreement  shall be used by CBC only to
manage  information  used in the operations of CBC's own donor blood banks,  and
shall not be used for,  or on behalf of,  others  except as  expressly  provided
herein. CBC shall not, directly or indirectly,  or; copy, duplicate,  or furnish
to others any  physical or magnetic  version of the  Software.  CBC shall notify
Hemocare  immediately of the unauthorized  possession,  use, or knowledge of any
item supplied to CBC pursuant to this License Agreement.

     11. License  Agreement.  This License Agreement shall bind and inure to the
benefit of CBC and its  successors  and  assigns by merger or  acquisition,  and
shall bind and inure to the benefit of Hemocare and its  successors  and assigns
by merger or acquisition.

     12.  Arbitration.  Any controversy or claim between the parties arising out
of, or relating to, this License Agreement or its performance or breach shall be
settled by arbitration in New York, N.Y. if arbitration is commenced by CBC, and
in Dallas,  Texas,  if  arbitration  is commenced by Hemocare.  In each case the
arbitration  will be conducted in  accordance  with the  Commercial  Arbitration
Rules of the

                                       15
<PAGE>

American  Arbitration  Association,  and judgment  entered upon the award by the
arbitrator may be entered in any court having jurisdiction thereof.

     13.  Governing  Law.  This  License  Agreement  shall be  governed  by, and
construed in accordance  with,  the law of Texas without regard for conflicts of
law rules.

     14.  Purchase  Agreement . This  License  Agreement  is being  entered into
simultaneously with a Purchase Agreement pursuant to which Hemocare is acquiring
tide to the Software from CBC. In the event of any conflict between this license
Agreement and the Purchase Agreement, the Purchase Agreement shall control.

     15. General.  This License Agreement and the Purchase Agreement contain the
complete and  exclusive  agreement  between the parties,  supersede  any and all
prior oral or written communications,  proposals, and agreements, and may not be
waived or modified except by written agreement of the parties

     WHEREFORE, the parties have caused this License Agreement to be executed by
their duly authorized representatives.

Carter BloodCare                             Hemocare, a division of
                                             Mediware Information Systems, Inc.

By:                                          By:  /s/  Lawrence Auriana
     ---------------------------                  ----------------------------
     Chairman                                     Chairman

                                       16
<PAGE>

                                   Schedule A

                          To Software License Agreement

Junior programmers and software technicians                $50 per hour

Senior programmers and software technicians                $75 per hour

                                       17
<PAGE>

                                  BILL OF SALE

Carter BloodCare,  a not-for-profit Texas Corporation  ("CBC"),  pursuant to the
Purchase  Agreement  dated November 1, 1999 between CBC and Hemocare,  the blood
bank  division of Mediware  Information  Systems,  Inc., a New York  Corporation
("Hemocare"),  (the "Agreement"),  and for good and valuable consideration to it
in hand paid,  receipt  of which is hereby  acknowledged,  does sell,  transfer,
convey,  assign and deliver to Hemocare,  its  successors and assigns (a) all of
CBC's right, title and interest in the computer software information  management
systems called the LifeTrak(TM),/Donor product,  LifeTrak-/Distribution product,
and LifeTrak(TM)/Lab  product (other than the "'Exclusive Module" referred to in
the  Agreement),  (the  "Software")  owned by CBC and any and all  improvements,
modifications,  enhancements  to the  Software  in  which  CBC has an  interest,
whether  on the  date of this  bill of sale or at a later  date,  (b) all of CBC
ownership of and right,  title and interest to the  applications to the Food and
Drug Administration ("FDA") under 5 1 0(k) for clearance of the Software and all
right,  title and interest of CBC in the "clearance" of the Software for use and
for sale now or hereafter  granted by FDA and (c) the name, mark, trade name and
trademark  "LifeTrak-"  and the good will of the  business  associated  with and
symbolized by the said marks, such name, trade name and trademark, including all
rights to, and applications for,  registration;  all of the foregoing  Software,
rights to  clearance  and name to include the right to use and enjoy the same in
perpetuity within and without the United States of America. CBC warrants that it
has not  encumbered  any of the foregoing or conveyed any interest  therein to a
third party other than as arising out of the Third Party  Agreement  referred to
in the Agreement.

     TO HAVE AND TO HOLD the same unto  Transferee,  its successors and assigns,
forever, from and after the date hereof

     IN WITNESS  WHEREOF,  Carter  BloodCare  has executed  this Bill of Sale on
November 1, 1999.

                                        CARTER BLOODCARE

                                        By:    /s/ M.H. Sayers
                                               --------------------------

                                        Name:  M.H. Sayers
                                               --------------------------

                                        Title: C.E.O
                                              --------------------------

                                       18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]